the compound that protects your dopamine on stims. nobody in this space runs it.

if you're running modafinil 5 days a week and stacking phenylpiracetam or adderall on top of it, your dopamine system is quietly wearing down.

you won't feel it yet.

you will in 18-24 months. the shape of it:

• flat mornings you can't explain
• same dose stops working
• more compound needed to hit the same output
• whole stack quietly stops doing what it used to

that spiral is receptor downregulation and it comes from every DAT inhibitor in your rotation.

modafinil, adderall, phenyl, vyvanse.

all doing the same thing at the synapse. forcing dopamine to stay there longer. your receptor adapts by desensitizing. the sharper you were 6 months ago, the more you notice it going.

there is ONE mechanism in pharmacology that raises dopaminergic tone without also driving the downregulation.

it's called MAO-B inhibition.

nobody in this space runs it.

the class and what it actually does

monoamine oxidase is an enzyme that breaks down dopamine, norepinephrine, serotonin, and phenethylamine. two isoforms.

MAO-A is the primary breakdown pathway for serotonin and dietary tyramine. sits mostly in the gut and liver.

MAO-B is the primary breakdown pathway for dopamine and phenethylamine. sits mostly in the brain.

inhibit the enzyme, the monoamines it normally clears build up in the synapse. depending on which isoform you're hitting and how selectively, you get very different profiles.

this is a completely different mechanism than what everything else in the space does. SSRIs block reuptake, forcing existing serotonin to stay in the synapse longer. MAOIs prevent the breakdown itself, letting the pool of transmitter grow. different downstream profile entirely.

why nobody runs it

they saw "MAOI" on a warning label. read "hypertensive crisis, avoid aged cheese, avoid every SSRI." closed the tab.

that warning was written for phenelzine in 1965. antidepressant dose, 60mg, irreversible, non-selective. that compound at that dose is legit dangerous. the risk is real.

the ironic part: those old blanket MAOIs actually beat SSRIs for atypical depression in most head-to-head measures. the tyramine risk and the reputation buried them. the efficacy was there the whole time. psychiatrists who know the literature quietly resent this.

and the problem is that same warning got copy-pasted onto every MAOI that came after.

selegiline at 5mg has a different mechanism, different selectivity, different dose range from phenelzine at 60mg. rasagiline is even cleaner. moclobemide is reversible entirely, which means dietary tyramine just competes for the enzyme instead of getting blocked outright. the modern low-dose selective MAOIs share basically none of the risk profile of the old compound the warning was written for.

the space just never got the memo cause nobody had a commercial reason to send it.

this is not research chem territory

before you write it off, look at the actual literature behind these:

• selegiline (jumex, eldepryl) has been the standard first-line parkinson's protocol since the 1980s
• the DATATOP trial (published NEJM 1993) proved selegiline actually slows the rate of dopamine neuron death in humans. mechanism: reduced dopamine oxidation, preserved dopamine neurons, mitochondrial support
• jozsef knoll, the guy who synthesized selegiline in the 1960s, ran it daily on himself for 40 years and lived to 87
• moclobemide has been prescribed across europe and australia for depression since 1990. 30+ years of prescribing data
• rasagiline (azilect) is FDA-approved and standard of care in parkinson's now

this is one of the most studied compound classes in pharmacology. it's just sitting outside the biohacker meta cause the biohacker meta runs on 20-year-old forum warnings instead of the actual literature.

what MAO-B inhibition actually does for you

three things nothing else in the space does.

1. it preserves the dopamine you already released.

DAT inhibitors like modafinil force dopamine to stay in the synapse longer, which drives your receptors to downregulate. MAO-B blocks the enzyme that BREAKS DOWN dopamine after it's already been released. so you're not adding more stimulation on top of stimulation. the dopamine your neuron released gets to do its job for longer, without the receptor wear that DAT inhibitors cause.

2. it eliminates a specific oxidative wear cycle.

every time MAO-B breaks down a dopamine molecule, it produces hydrogen peroxide as a byproduct. dopamine neurons in the substantia nigra already carry the highest metabolic load in the brain and depend heavily on mitochondrial complex 1, which is the primary site of ROS generation. that H2O2 is the actual mechanism of wear on the exact neurons you can't afford to lose. block MAO-B, you cut the oxidative load right at the source.

3. activity enhancement.

this is the deprenyl literature knoll himself built out later in his career. at low doses selegiline enhances impulse-mediated catecholamine release through a separate mechanism from MAO inhibition (still being characterized, probably TAAR1-related). net effect: your dopamine neurons release more per firing event, but only when they're actually firing. this is the mechanism the second-generation compounds PPAP and BPAP were designed around.

no other class does these things. the receptor-density work of uridine, the synaptogenesis work of dihexa, the AMPA work of racetams, all valuable, all different. MAOIs sit in their own category and the effects don't come from anywhere else.

for a 23 year old running stims 5 days a week trying to still be sharp on client calls at 28, that's the whole game.

the compounds worth running

> selegiline 1-5mg daily

> selective for MAO-B in this range. loses selectivity above 10mg so don't push past it. what you feel is a slow upward shift in baseline drive and mood over 1-2 weeks. not stimulating in the acute sense. waking up flat just quietly stops happening.

> rasagiline 0.5-1mg daily

> selegiline's cleaner cousin. no amphetamine metabolites (selegiline produces trace methamphetamine, which is fine but rasagiline skips it entirely). stronger evidence for neuroprotection independent of MAO inhibition through a mitochondrial mechanism. tighter dose window, better molecule tbh, just harder to source clean.

> moclobemide 150-600mg daily

> this is the one nobody in the space knows exists. reversible MAO-A inhibitor. reversible means dietary tyramine competes for the enzyme instead of getting blocked outright. you can eat aged cheese on this. hits serotonin so the mood profile lands closer to an SSRI. faster onset than SSRIs, no sexual side effects, no discontinuation syndrome. not approved in the US, standard prescription across europe and australia. if you've tried SSRIs and got nothing (or got the sexual side effects) this is the mechanism that actually works for a lot of people.

> 9-me-bc 10-30mg daily

> reversible MAO-B inhibitor with BDNF and GDNF upregulation and mitochondrial complex 1 support stacked on top. same neuroprotection angle as selegiline, broader downstream profile. run on OFF days from stims, not on top of them.

> harmine / harmaline 10-25mg

> the "natural" MAOIs from syrian rue and banisteriopsis caapi. reversible MAO-A inhibitors with additional activity at 5-HT2A and imidazoline receptors. at ayahuasca doses (100-300mg) these are serious compounds with real interaction risk. at 10-25mg microdoses users report mild mood elevation and increased emotional connectivity without the psychedelic component. reversible mechanism means tyramine risk is limited but not zero, interaction risk with serotonergics still real. not a daily-use recommendation. worth knowing about cause the mechanism is legit.

the interactions that actually matter

the real list is short and specific:

• no SSRIs
• no SNRIs
• no tramadol (serotonergic on top of the opioid mechanism, catches people out)
• no DXM
• no MDMA
• no high-dose 5-HTP or l-tryptophan
• no stacking 2 MAOIs at once
• no methylene blue above 1mg/kg

that's the whole list. everything else in a normal stack is fine.

why sourcing is 90% of getting this right

selegiline is one of the most commonly counterfeited compounds in the grey market. the branded pharma product (jumex) is expensive and the research chem sites push underdosed generic tablets that either do nothing or overshoot the MAO-B selective range and become dangerous at that point.

moclobemide isn't approved in the US at all. 80% of what's floating around online is garbage.

run pharma-grade or don't bother. the compound literally only works if what's in the vial matches the label.

the full protocol lives in the vault

what's above is the pharmacology. what's in the vault is the actual protocol i run, free:

• the exact daily stack for MAO-B neuroprotection alongside modafinil 5 days a week
• the cycle rotation between selegiline and rasagiline
• which specific brand of each compound actually contains what the label says
• the 1 supplier i trust for 9-me-bc clean (dm @modamade for the specific link, not going in the vault)

on top of that, every protocol i've ever written is already in there:

• the full IQmaxxing foundation guide
• the drive protocol
• the sleep protocol
• the learning protocol
• the processing-speed protocol
• the off-switch and anxiety protocol
• the high-stakes-day protocol
• the sex protocol
• the weed-quitting protocol
• the stress protocol
• the longevity-while-running-stims protocol
• the "evil chemical edition" IQmaxxing follow-up
• and much more...

all of it, free:

t.me/t33vault

t33